Zoia Levashova

Medicine · Health Sciences

17h-index832citations37works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(9), Angiogenesis and VEGF in Cancer(8), HER2/EGFR in Cancer Research(8), Cell Adhesion Molecules Research(8), Cancer, Hypoxia, and Metabolism(6)

Publications37 total

Supplementary Tables S1-S4 from Treating Tissue Factor–Positive Cancers with Antibody–Drug Conjugates That Do Not Affect Blood Clotting
2023Open Access
Supplementary Tables S1-S4 from Treating Tissue Factor–Positive Cancers with Antibody–Drug Conjugates That Do Not Affect Blood Clotting
2023Open Access
Supplementary Figures S1-S6 from Treating Tissue Factor–Positive Cancers with Antibody–Drug Conjugates That Do Not Affect Blood Clotting
2023Open Access
Data from Treating Tissue Factor–Positive Cancers with Antibody–Drug Conjugates That Do Not Affect Blood Clotting
2023Open Access
Supplementary Figures S1-S6 from Treating Tissue Factor–Positive Cancers with Antibody–Drug Conjugates That Do Not Affect Blood Clotting
2023Open Access
Data from Treating Tissue Factor–Positive Cancers with Antibody–Drug Conjugates That Do Not Affect Blood Clotting
2023Open Access
Supplementary Materials and Methods from Treating Tissue Factor–Positive Cancers with Antibody–Drug Conjugates That Do Not Affect Blood Clotting
2023Open Access
Supplementary Materials and Methods from Treating Tissue Factor–Positive Cancers with Antibody–Drug Conjugates That Do Not Affect Blood Clotting
2023Open Access
Treating Tissue Factor–Positive Cancers with Antibody–Drug Conjugates That Do Not Affect Blood Clotting
Molecular Cancer Therapeutics·2018· 41 cited
Targeted scVEGF/177Lu radiopharmaceutical inhibits growth of metastases and can be effectively combined with chemotherapy
EJNMMI Research·2016· 10 citedOpen Access
Additional file 1: Figure S1. of Targeted scVEGF/177Lu radiopharmaceutical inhibits growth of metastases and can be effectively combined with chemotherapy
Figshare·2016Open Access
Antibody–Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs
Molecular Pharmaceutics·2015· 150 citedOpen Access
A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies
Blood Cancer Journal·2015· 17 citedOpen Access
CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma.
PubMed·2015· 42 citedOpen Access
Antitumor activity of an anti‐<scp>CD</scp>98 antibody
International Journal of Cancer·2014· 69 citedOpen Access
[99mTc]Annexin V-128 SPECT Monitoring of Splenic and Disseminated Listeriosis in Mice: a Model of Imaging Sepsis
Molecular Imaging and Biology·2014· 8 cited
Tc99m-annexin V-128 SPECT imaging of listeriosis in mice
2014
In Vivo Imaging of Apoptosis in Early Aneurysm Development in Marfan Syndrome
Journal of Surgical Research·2012
Targeted Systemic Radiotherapy with scVEGF/<sup>177</sup>Lu Leads to Sustained Disruption of the Tumor Vasculature and Intratumoral Apoptosis
Journal of Nuclear Medicine·2011· 16 citedOpen Access
Characterization of a Recombinant Form of Annexin VI for Detection of Apoptosis
Bioconjugate Chemistry·2010· 4 cited
page 1 of 2Next →

Frequent Co-authors

Francis G. Blankenberg(18), Marina V. Backer(13), Joseph M. Backer(13), Jan-Willem Theunissen(9), Allen G. Cai(9), Maryam M. Bhatti(9), Anthony B. Cooper(9), Ryan Dorfman(9), Sebastián Guelman(9), Thi‐Sau Migone(9), Andrew D. Avery(8), Lawrence Chinn(4), Edward H. van der Horst(4), Abel Bermudez(3), Sindy Liao-Chan(3), Mark R. Flory(3), Belinda Cairns(3), John Pizzonia(3), В. Ф. Кобзев(3), Edward Ha(2)